Biotalys Nv · EURONEXT:BTLS

Biotalys Nv — FY2025 Earnings Presentation

12 slides from Biotalys Nv's earnings presentation, Apr 29, 2026

  1. Slide 1: Full Year 2025 Results & Business Highlights

    Full Year 2025 Results & Business Highlights 29 April 2026

  2. Slide 2: Disclaimer

    Disclaimer • This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information p

  3. Slide 3: Carlo Boutton, CEO (interim) & Chief Scientific Officer

    Carlo Boutton CEO (interim) & Chief Scientific Officer

  4. Slide 4: Regulatory inflection achieved with first of its kind protein pesticide registration in USA

    Regulatory inflection achieved with first of its kind protein pesticide registration in USA Estimated registration timelines per geography EU public consultation EVOCA 2025 2026 now initiated! 2029- EVOCA NG 2029 2030 BioFun-6 2030-31 2034-35 Maximum residue level (MRL) exemption for EVOCA EPA exemp

  5. Slide 5: Focused pipeline maximizes near-term value while preserving platform upside

    Focused pipeline maximizes near-term value while preserving platform upside Global Partnership Program Target Market Discovery Development Registration Market Size* Agreement EVOCA Botrytis, powdery High-value fruits & Pilot product 1st Gen mildew vegetables EVOCA Botrytis, powdery High-value fruits

  6. Slide 6: Strategic refocus and operational streamlining

    Strategic refocus and operational streamlining What Changes Restructuring & Streamlining Quantified Impact Post-Reset Steady State Refocus organization on highest priority programs Headcount reduction, including leadership Streamline organization with new Reduced cash burn to end of 2028 strategy St

  7. Slide 7: Outlook 2026

    Outlook 2026 • Advance EVOCA NG in terms of process development as regulatory work and BioFun-6 with ongoing field trials • Continue optimizing production and manufacturing plans with 21st.Bio and network of CMO’s • Progress other pipeline programs BioFun-7 and BioIns-2, while opening BioFun-4 and -

  8. Slide 8: Luc Van fraeyenhoven, Chief Financial Officer

    Luc Van fraeyenhoven Chief Financial Officer

  9. Slide 9: FY 2025 key financial highlights

    FY 2025 key financial highlights In € thousands 2025 2024 Other operating income 3,043 3,183 Research and development expenses (13,272) (10,959) General and administrative expenses (5,615) (5,716) Operating loss (15,844) (13,492) Loss of the period (15,759) (13,188) Net cash inflow (outflow) of the

  10. Slide 10: Financing and cash runway update

    Financing and cash runway update • Current cash runway until end of May 2026 • Biotalys is in well-advanced negotiations with a number of investors to support the execution of its strategic refocus • Next to an equity injection, Biotalys is also exploring other alternative dilutive and non-dilutive

  11. Slide 11: Closing remarks and Q&A

    Closing remarks and Q&A Carlo Boutton Luc Van fraeyenhoven CEO ad interim Chief Financial Officer Chief Scientific Officer 11

  12. Slide 12: Slide 12

Biotalys — FY2025 Earnings Presentation on 6ix